Cited by 5,164Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Open access

Giugliano, Robert P., Ruff, Christian T., Braunwald, Eugene, Murphy, Sabina A., Wiviott, Stephen D., Halperin, Jonathan L., Waldo, Albert L., Ezekowitz, Michael D., Weitz, Jeffrey I., Špinar, Jindřich, Ruzyllo, Witold, Ruda, Mikhail, Koretsune, Yukihiro, Betcher, Joshua, Shi, Minggao, Grip, Laura T., Patel, Shirali P., Patel, Indravadan, Hanyok, James J., Mercuri, Michele, Antman, Elliott M.·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1310907

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1310907

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citation
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Self-citation
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 1

Grip LT, 2013, Hot Topics Cardiol, 31, 7

Sorted by citations

Items 501–600 of 1,005

Systematic review with meta‐analysis: the risk of major gastrointestinal bleeding with non‐vitamin K antagonist oral anticoagulants
Caldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 68
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
Biase, L. D. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002776 · Cited by 66
Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease
Brutto, V. J. D., Chaturvedi, S., Diener, H., Romano, J. G., & Sacco, R. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.039 · Cited by 71
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 66
European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
Hobbs, R. F., Taylor, C. J., Geersing, G. J., Rutten, F. H., Brouwer, J. R., & on behalf of the European Primary Care Cardiovascular Society (EPCCS) SPAF working group (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315571890 · Cited by 67
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
Hohnloser, S. H., Basic, E., & Näbauer, M. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1098-x · Cited by 65
Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort
Son, M. K., Lim, N.-K., Kim, H. W., & Park, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179687 · Cited by 67
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation
Hohmann, C., Hohnloser, S. H., Jacob, J., Walker, J., Baldus, S. E., & Pfister, R. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1683422 · Cited by 65
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
Maura, G., Billionnet, C., Drouin, J., Weill, A., Neumann, A., & Pariente, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026645 · Cited by 67
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-024-01771-5 · Cited by 66
A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation
Obamiro, K. O., Chalmers, L., & Bereznicki, L. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0171-6 · Cited by 63
Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials
Sahay, S., y, L. N.-F., Rodés‐Cabau, J., Jiménez‐Quevedo, P., Salinas, P., Biagioni, C., Nuñez-Gil, I. J., Gonzalo, N., de Agustín, J. A., Trigo, M. D., et al. (2016) · Heart · doi:10.1136/heartjnl-2016-309782 · Cited by 64
Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Steinberg, B. A., Shrader, P., Thomas, L. E., Ansell, J., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., O'Brien, E. C., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.024 · Cited by 65
Global Prospective Safety Analysis of Rivaroxaban
Kirchhof, P. F., Radaideh, G. A., Kim, Y., Lanas, F. T., Haas, S. K., Amarenco, P., Turpie, A. G. G., Bach, M., Lambelet, M., Hess, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.058 · Cited by 64
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Slot, K. B., & Berge, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008980.pub3 · Cited by 68
Atrial fibrillation
Thomas, M., Wu, L., & Win, K. (2014) · Journal of Biomedical Research · doi:10.7555/jbr.28.20130191 · Cited by 68
Risk of gastrointestinal bleeding during anticoagulant treatment
Lanas-Gimeno, A., & Lanas, A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1325870 · Cited by 65
Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population‐Based Study
Yu, A., Malo, S., Svenson, L. W., Wilton, S. B., & Hill, M. D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007129 · Cited by 64
Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Deng, Y., Tong, Y., Deng, Y., Zou, L., Li, S., & Chen, H. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012540 · Cited by 62
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
Kustos, S. A., & Fasinu, P. S. (2019) · Medicines · doi:10.3390/medicines6040103 · Cited by 63
“In the ENGAGE AF-TIMI trial, a phase III trial of edoxaban in the United States, edoxaban was effective, and non-inferior to warfarin in patients with NVAF, with a significantly less incidence of bleeding and cardiovascular death [101].”
Method
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation
Paciaroni, M., Agnelli, G., Ageno, W., & Caso, V. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0217 · Cited by 62
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation
Flack, K. F., Desai, J., Kolb, J. M., Chatterjee, P., Wallentin, L. C., Ezekowitz, M. D., Yusuf, S., Connolly, S. J., Reilly, P. A., Brueckmann, M., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.011 · Cited by 62
Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology
Görenek, B., Halvorsen, S., Kudaiberdieva, G., Bueno, H., Gelder, I. C. V., Lettino, M., Marín, F. R., Masip, J., Mueller, C. E., Okutucu, S., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872619894255 · Cited by 70
Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective
Piccini, J. P., Allred, J. D., Bunch, T. J., Deering, T. F., Biase, L. D., Hussein, A. A., Lewis, W. R., Mittal, S., Natale, A., Osorio, J., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.04.033 · Cited by 63
Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gu, Z., Zhou, L., Shen, L., Zhang, C., Pu, J., Lin, H., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00348 · Cited by 62
“…1 and Table S1) (Connolly et al., 2009; Schulman et al., 2009, 2013, 2014; EINSTEIN Investigators et al., 2010; Granger et al., 2011; Patel et al., 2011; EINSTEIN–PE Investigators et al., 2012; Hori et al., 2012; Agnelli et al., 2013; Giugliano et al., 2013; HokusaiVTE Investigators et al., 2013).”
BackgroundInfluential
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 69
Acute, periprocedural and longterm antithrombotic therapy in older adults
Andreotti, F., Geisler, T., Collet, J., Gigante, B., Gorog, D. A., Halvorsen, S., Lip, G. Y. H., Morais, J., Navarese, E. P., Patrono, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac515 · Cited by 64
Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves
Yadlapati, A., Groh, C. A., Malaisrie, S. C., Gajjar, M. M., Kruse, J. T., Meyers, S. N., & PASSMAN, R. S. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0919-z · Cited by 61
An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics
Mendell, J., Johnson, L., & Chen, S. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.550 · Cited by 62
Ablation of Atrial Fibrillation
Link, M. S., Haı̈ssaguerre, M., & Natale, A. (2016) · Circulation · doi:10.1161/circulationaha.116.021727 · Cited by 64
Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation
Tawfik, A., BIELECKI, J. M., Krahn, M. D., Dorian, P., Hoch, J. S., Boon, H. S., Husereau, D., & Pechlivanoglou, P. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s105165 · Cited by 60
Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis
Kim, I., Kim, H.-J., Kim, T., Uhm, J., Joung, B., Lee, M., & Pak, H. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.01.015 · Cited by 63
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis
Niessner, A., Tamargo, J. L., Morais, J., Koller, L., Waßmann, S., Husted, S., Torp-Pedersen, C. T., Kjeldsen, K. P., Lewis, B. S., Drexel, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv676 · Cited by 60
Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life
Becattini, C., Franco, L., Beyer‐Westendorf, J., Masotti, L., Nitti, C., Vanni, S., Manina, G., Cattinelli, S., Cappelli, R., Sbrojavacca, R., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.117 · Cited by 63
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
Benz, A. P., Hohnloser, S. H., Eikelboom, J. W., Carnicelli, A., Giugliano, R. P., Granger, C. B., Harrington, J., Hijazi, Z., Morrow, D. A., Patel, M. R., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad200 · Cited by 60
An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery
Johnston, S. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.12.010 · Cited by 65
Pharmacokinetics of new oral anticoagulants: implications for use in routine care
Ingrasciotta, Y., Crisafulli, S., Pizzimenti, V., Marcianò, I., Mancuso, A., Andò, G., Corrao, S., Capranzano, P., & Trifirò, G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530213 · Cited by 60
Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis
Caldeira, D., Nunes-Ferreira, A., Rodrigues, R. O., Vicente, E., Pinto, F. J., & Ferreira, J. J. (2018) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2018.12.013 · Cited by 60
Continued Versus Interrupted Oral Anticoagulation During Transfemoral Transcatheter Aortic Valve Implantation and Impact of Postoperative Anticoagulant Management on Outcome in Patients With Atrial Fibrillation
Mangner, N., Crusius, L., Haußig, S., Woitek, F. J., Kiefer, P., Stachel, G., Leontyev, S., Schlotter, F., Spindler, A., Höllriegel, R., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.12.042 · Cited by 61
Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation
Shah, S. J., Singer, D. E., Fang, M. C., Reynolds, K., Go, A. S., & Eckman, M. H. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006212 · Cited by 60
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
Barbui, T., Stefano, V. D., Carobbio, A., Iurlo, A., Álvarez‐Larrán, A., Cuevas, B., Ferrer‐Marín, F., Vannucchi, A. M., Palandri, F., Harrison, C. N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01279-1 · Cited by 60
Global Burden of Atrial Fibrillation and Flutter by National Income: Results From the Global Burden of Disease 2019 Database
Ohlrogge, A. H., Brederecke, J., & Schnabel, R. B. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030438 · Cited by 62
“41 In the ENGAGE-AF TIMI 48 (The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation– Thrombolysis in Myocardial Infarction 48) trial, for example, 62.4% of patients were recruited in high-income countries, 28.2% in upper- middle-income countries, 9.3% in lower-…”
Influential
Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation – Shinken Database Analysis –
Suzuki, S. S., Otsuka, T., Sagara, K., Semba, H., Kano, H., Matsuno, S., Takai, H., Kato, Y., Uejima, T., Oikawa, Y., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1237 · Cited by 59
Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis
Spronk, H. M. H., Padró, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G. D. O., D’Alessandro, E., Wenzel, P., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0492 · Cited by 62
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
Haas, S. K., Camm, A. J., Bassand, J., Angchaisuksiri, P., Cools, F. J. S., Corbalan, R. L., Gibbs, H. H., Jacobson, B. F., Koretsune, Y., Mantovani, L. G., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.03.013 · Cited by 59
Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation
Kosmidou, I., Liu, Y., Alu, M. C., Liu, M., Madhavan, M. V., Chakravarty, T., Makkar, R., Thourani, V. H., BIVIANO, A. B., Kodali, S., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.06.001 · Cited by 59
Targeted thromboelastographic (TEG) blood component and pharmacologic hemostatic therapy in traumatic and acquired coagulopathy
Walsh, M., Fritz, S., Hake, D., Son, M., Greve, S., Jbara, M., Chitta, S., Fritz, B., Miller, A., K Bader, M., et al. (2016) · Current Drug Targets · doi:10.2174/1389450117666160310153211 · Cited by 58
Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 62
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19
Abraham, S., Nohria, A., Neilan, T. G., Asnani, A. H., Saji, A. M., Shah, J., Lech, T. K., Grossman, J., Abraham, G. M., McQuillen, D. P., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.800 · Cited by 60
“Ritonavir inhibits P-gp and can potentially increase the concentration of edoxaban.(15) In the ENGAGE AF-TIMI 48 (Global Study to Assess the Safety and Effectiveness of Edoxaban [DU-176b] vs Standard Practice of Dosing With Warfarin in Patients With Atrial FibrillationThrombolysis In Myocardial Infarction 48; NCT00781…”
Background
Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China
Yang, X., Li, Z., Zhao, X., Wang, C., Liu, L., Wang, C., Pan, Y., Li, H., Wang, D., Hart, R. G., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.011833 · Cited by 58
Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48
Plitt, A., Ezekowitz, M. D., Caterina, R. D., Nordio, F., Peterson, N., Giugliano, R. P., & on behalf of the ENGAGE AF‐TIMI 48 Investigators (2016) · Clinical Cardiology · doi:10.1002/clc.22537 · Cited by 58
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Shah, A., Shewale, A. R., Hayes, C. J., & Martin, B. C. (2016) · Stroke · doi:10.1161/strokeaha.115.012325 · Cited by 58
Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation
Makani, A., Saba, S., Jain, S. K., Bhonsale, A., Sharbaugh, M. S., Thoma, F. W., Wang, Y., Marroquin, O. C., Lee, J. S., Estes, N. A. M., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.033 · Cited by 58
Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta‐analysis
Kuo, H.-C., Liu, F., Chen, J., Cherng, Y., Tam, K., & Tai, Y. (2020) · Clinical Cardiology · doi:10.1002/clc.23336 · Cited by 58
“NOACs are non-inferior for prevention of stroke in patients with atrial fibrillation and associated with less bleeding compared to warfarin.(34)”
Background
Stroke prevention strategies in high-risk patients with atrial fibrillation
Kotalczyk, A., Mazurek, M., Kalarus, Z. F., Potpara, T., & Lip, G. Y. H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00459-3 · Cited by 60
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
Steffel, J., Ruff, C. T., Yin, O. Q. P., Braunwald, E., Park, J., Murphy, S. A., Connolly, S. J., Antman, E. M., & Giugliano, R. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.053 · Cited by 58
A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants
Cohen, A. T., Hill, N. R., Luo, X., Masseria, C., Abariga, S. A., & Ashaye, A. O. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.114 · Cited by 57
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
Tsai, C.-T., Liao, J., Chiang, C., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Chung, F., Chao, T., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6424 · Cited by 57
Safety of direct oral anticoagulants in patients with advanced liver disease
Semmler, G., Pomej, K., Bauer, D. J. M., Balcar, L., Simbrunner, B., Binter, T., Hartl, L., Becker, J., Pinter, M., Quehenberger, P., et al. (2021) · Liver International · doi:10.1111/liv.14992 · Cited by 57
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
Hess, P. L., Mirro, M. J., Diener, H., Eikelboom, J. W., Al‐Khatib, S. M., Hylek, E. M., Bosworth, H. B., Gersh, B. J., Singer, D. E., Flaker, G., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.04.007 · Cited by 58
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan
Fuji, T., Wang, C.-J., Fujita, S., Kawai, Y., Kimura, T., & Tachibana, S. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.05.029 · Cited by 58
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 58
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review
Caterina, R. D., & Lip, G. Y. H. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1102-5 · Cited by 57
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study
Poli, D., Antonucci, E., Pengo, V., Migliaccio, L., Testa, S., Lodigiani, C., Coffetti, N., Facchinetti, R., Serricchio, G., Falco, P., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.04.042 · Cited by 57
Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review
Ding, M., & Qiu, C. (2018) · Current Epidemiology Reports · doi:10.1007/s40471-018-0159-7 · Cited by 57
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
Sulzgruber, P., Waßmann, S., Semb, A. G., Doehner, W., Widimský, P., Gremmel, T., Kaski, J. C., Savarese, G., Rosano, G. M. C., Borghi, C., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz016 · Cited by 58
“(18-21) Compared to warfarin, the risk of major bleeding was significantly”
Background
Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis
Coleman, C. I., Kreutz, R. H., Sood, N. A., Bunz, T. J., Meinecke, A., Eriksson, D., & Baker, W. L. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619868535 · Cited by 58
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
Bengtson, L. G. S., Lutsey, P. L., Chen, L. Y., MacLehose, R. F., & Alonso, Á. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.08.010 · Cited by 57
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
Camire, R. M. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02456-w · Cited by 59
Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants
Cate, H. T., Henskens, Y., & Lance, M. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s126265 · Cited by 56
Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
Lip, G. Y. H., Pan, X., Kamble, S., Kawabata, H., Mardekian, J., Masseria, C., & Phatak, H. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195950 · Cited by 56
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease
Marston, N., Patel, P. N., Kamanu, F., Nordio, F., Melloni, G. E. M., Roselli, C., Gurmu, Y., Weng, L.-C. C., Bonaca, M. P., Giugliano, R. P., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051927 · Cited by 56
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
Lawal, O. D., Aronow, H. D., Shobayo, F. O., Hume, A. L., Taveira, T. H., Matson, K. L., Zhang, Y., & Wen, X. (2023) · Circulation · doi:10.1161/circulationaha.122.060687 · Cited by 54
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
Ip, B. Y. M., Lau, K. K., Ko, H., Lau, L., Yao, A., Wong, G. L., Yip, T. C., Leng, X., Chan, H. H. W., Chan, H., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207422 · Cited by 61
Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events With Ineligibility for Oral Anticoagulation
Sievert, H., Rasekh, A., Bartus, K., Morelli, R., Fang, Q., Kuropka, J., Le, D. L., Gafoor, S. A., Heuer, L., Safavi‐Naeini, P., et al. (2015) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2015.08.005 · Cited by 55
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
Lip, G. Y. H., Collet, J., Caterina, R. D., Fauchier, L., Lane, D. A., Larsen, T. B., Marín, F. R., Morais, J., Narasimhan, C., Olshansky, B., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th-17-10-0709 · Cited by 55
Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry
Koretsune, Y., Yamashita, T., Akao, M., Atarashi, H., Ikeda, T., Okumura, K., Shimizu, W., Tsutsui, H., Toyoda, Ḱ., Hirayama, A., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0094 · Cited by 55
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Mariani, M. V., Magnocavallo, M., Straito, M., Piro, A., Severino, P., Iannucci, G., Chimenti, C., Mancone, M., Rocca, D. G. D., Forleo, G. B., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02304-3 · Cited by 56
Cerebral Venous Thrombosis
Field, T. S., & Hill, M. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025334 · Cited by 55
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis
Chen, H.-Y., Ou, S., Huang, C., Lee, P., Chou, K.-J., Lin, P., & Su, Y. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01016-7 · Cited by 56
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
Caso, V., de Groot, J. R., Sanmartín, M., Segura, T., Blomström‐Lundqvist, C., Hargroves, D. R., Antoniou, S., Williams, H., Worsley, A., Harris, J. E., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-321114 · Cited by 57
Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: A report from a prospective European observational registry
Mei, D. A., Imberti, J. F., Bonini, N., Romiti, G. F., Corica, B., Proietti, M., Vitolo, M., Lip, G. Y. H., & Boriani, G. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.06.022 · Cited by 54
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., & Hobbs, F. D. R. (2015) · EP Europace · doi:10.1093/europace/euv068 · Cited by 54
Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
Janžič, A., & Kos, M. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0246-7 · Cited by 54
Vitamin K antagonists with or without long‐term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events
Lemesle, G., Ducrocq, G., Elbez, Y., BELLE, E. V., Goto, S., Cannon, C. P., Bauters, C., Bhatt, D. L., Steg, P. G., & for the REACH Investigators (2017) · Clinical Cardiology · doi:10.1002/clc.22750 · Cited by 56
Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the “rubber effect”
Ziakas, P. D., Kourbeti, I. S., Poulou, L. S., Vlachogeorgos, G. S., & Mylonakis, E. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198674 · Cited by 54
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials
Wang, K.-L., Lópes, R. D., Patel, M. R., Buller, H. R., Tan, D. S., Chiang, C., & Giugliano, R. P. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy802 · Cited by 54
Stroke in the elderly
Sharrief, A. Z., & Grotta, J. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00021-2 · Cited by 59
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Schäfer, A., Flierl, U., Berliner, D., & Bauersachs, J. K. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06981-3 · Cited by 60
“The ENTRUST-AF PCI trial investigated the combination of the factor Xa-inhibitor edoxaban (in the approved dose of 1*60mg/day or 1*30mg/day in case of dose reduction criteria as in ENGAGE [14]) with mostly clopidogrel following PCI in AF.”
BackgroundMethodResultInfluential
Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors
Liu, M., Zaman, K., & Fortenberry, Y. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083897 · Cited by 54
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions
Paikin, J. S., Hirsh, J., Lauw, M. N., Eikelboom, J. W., Ginsberg, J. S., & Chan, N. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0918 · Cited by 53
A systematic review of patient‐reported outcomes associated with the use of direct‐acting oral anticoagulants
Afzal, S. K., Hasan, S. S., & Babar, Z. U. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13985 · Cited by 53
“Edoxaban was approved in 2015 after the result of the ENGAGE‐AF trial displaying noninferiority of edoxaban to warfarin.(8) These clinical studies emphasized the clinical efficacy of the DOACs vs warfarin with the enhanced benefit of reduced intracranial and major bleeding, but showed a higher risk of gastrointestinal…”
Method
Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system
Watson, R. A., Johnson, D. M., Dharia, R. N., Merli, G. J., & Doherty, J. U. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1772639 · Cited by 55
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 54
Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
Zeng, S., Zheng, Y., Jiang, J., Ma, J., Zhu, W., & Cai, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907197 · Cited by 53
Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion
Carvalho, P. E. P., Gewehr, D. M., Miyawaki, I. A., Nogueira, A., Felix, N. S., Garot, P., Darmon, A., Mazzone, P., Preda, A., Nascimento, B. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.010 · Cited by 53
Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Parrini, I., Canale, M. L., Giubilato, S., Cornara, S., Nesti, M., Rao, C. M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185955 · Cited by 61
“In the ENGAGE-AF TIMI 48 study evaluating edoxaban (30 and 60 mg) versus warfarin, in BMI categories between 18.5 and 40 mg/m 2 , no plasma variations were found, indicating comparable efﬁcacy and safety [148,149].”
Influential
Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives
Landmesser, U., Skurk, C., Tzikas, A., Falk, V., Reddy, V. Y., & Windecker, S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae398 · Cited by 56
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial
Shoamanesh, A., Field, T. S., Coutts, S. B., Sharma, M., Gladstone, D. J., Hart, R. G., Boriani, G., Wright, D. J., Sticherling, C., Birnie, D. H., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00475-7 · Cited by 53
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens
Providencia, R. A., Grove, E. L., Husted, S., Barra, S., Bovéda, S., & Morais, J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.002 · Cited by 52

Authors: Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., Mercuri, M., & Antman, E. M.
Affiliations: Brigham and Women's Hospital (US)
University Hospitals Cleveland Medical Center (US)
McMaster University (CA)
National Medical Research Center of Cardiology (RU)
Osaka National Hospital (JP)
IQVIA (United States) (US)
Daiichi Sankyo (United States) (US)
ORCID: Giugliano, Robert P.
Ruff, Christian T.
Wiviott, Stephen D.
Halperin, Jonathan L.
Weitz, Jeffrey I.
Špinar, Jindřich
Patel, Indravadan
Mercuri, Michele
Antman, Elliott M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-11-28
Volume: 369
Issue: 22
Pages: 2093-2104
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1310907
OpenAlex: W2096246254
Cited by: 5,164
References: 24
Citations by year: 2026: 201 · 2025: 280 · 2024: 344 · 2023: 419 · 2022: 405 · 2021: 469 · 2020: 505 · 2019: 443 · 2018: 487 · 2017: 454 · 2016: 494 · 2015: 378 · 2014: 266 · 2013: 12
FWCI: 260.36
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
HAL (submittedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Figshare (submittedVersion, cc-by)
IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Gilead Sciences
AtriCure
Boston Scientific Corporation
Medicines Company
Janssen Scientific Affairs
Bayer HealthCare
Eisai
St. Jude Medical
Biosense Webster
Janssen Pharmaceuticals
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: edoxaban, warfarin, atrial fibrillation, direct oral anticoagulants, factor Xa inhibitors, stroke and systemic embolism, major bleeding, non-inferiority, oral anticoagulation, time in therapeutic range, anticoagulant efficacy and safety, once-daily dosing
MeSH terms: Adult, Aged, Anticoagulants, Atrial Fibrillation, Cardiovascular Diseases, Double-Blind Method, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyridines, Thiazoles, Warfarin, Stroke, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks